Recombinant Human/Rhesus Macaque/Feline CXCL12/SDF-1 alpha


Recombinant Human/Rhesus Macaque/Feline CXCL12/SDF-1 alpha (Catalog # 350-NS) chemoattracts the BaF3 mouse pro-B cells transfected with human CXCR4. The ED50 for this effect is 0.15-0.6 ng/mL.
1 μg/lane of Recombinant Human/Rhesus Macaque/Feline CXCL12/SDF-1 alpha was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a single band at 7 kDa.

Product Details

Reactivity Hu, Fe, RMSpecies Glossary
Applications Bioactivity

Order Details

View Available Formulations
Catalog# & Formulation Size Price

Recombinant Human/Rhesus Macaque/Feline CXCL12/SDF-1 alpha Summary

Details of Functionality
Measured by its ability to chemoattract 5-10 day cultured human peripheral blood lymphocytes (PBL). The ED50 for this effect is 3‑9 ng/mL. Measured by its ability to chemoattract BaF3 mouse pro‑B cells transfected with human CXCR4. The ED50 for this effect is 0.15‑0.6 ng/mL.
E. coli-derived CXCL12/SDF-1 alpha protein
Accession #
N-terminal Sequence
Protein/Peptide Type
Recombinant Proteins
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Note
<0.01 EU per 1 μg of the protein by the LAL method.


  • Bioactivity
  • Bioactivity2
Theoretical MW
8.0 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
7 kDa, reducing conditions.
Read Publications using
350-NS in the following applications:

Packaging, Storage & Formulations

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein.
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.


This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human/Rhesus Macaque/Feline CXCL12/SDF-1 alpha

  • CXCL12 chemokine (C-X-C motif) ligand 12
  • CXCL12/SDF-1 alpha
  • IRH
  • PBSF
  • SCYB12
  • SDF1 alpha
  • SDF1
  • SDF1a
  • SDF1B
  • TLSF
  • TPAR1


SDF-1 alpha and SDF-1 beta are the first cytokines initially identified using the signal sequence trap cloning strategy from a mouse bone-marrow stromal cell line. These proteins were subsequently also cloned from a human stromal cell line as cytokines that supported the proliferation of a stromal cell-dependent pre-B-cell line.
SDF-1 alpha  and SDF-1 beta cDNAs encode precursor proteins of 89 and 93 amino acid residues, respectively. SDF-1 alpha and SDF-1 beta are encoded by a single gene and arise by alternative splicing. The two proteins are identical except for the four amino acid residues that are present in the carboxy-terminus of SDF-1 beta and absent from SDF-1 alpha . The amino acid sequence of SDF-1/PBSF identified the protein to be a member of the chemokine alpha subfamily that lacks the ELR domain. Unlike other known chemokine alpha and beta subfamily members that cluster on chromosomes 4 and 17, respectively, SDF-1/PBSF was mapped to chromosome 10q11.1. SDF-1/PBSF is highly conserved between species, with only one amino acid substitution between the mature human and mouse proteins. SDF-1/PBSF has been found to be a chemoattractant for T-lymphocytes and monocytes, but not neutrophils. SDF-1/PBSF was shown to be a ligand for CXCR4 (fusin/LESTR) receptor that functions as a co-receptor for lymphocyte-tropic HIV-1 strains. SDF-1/PBSF has been found to be a powerful inhibitor of infection by lymphocyte-tropic HIV-1 strains.

  1. Tashiro, K. et al. (1993) Science 261:600.
  2. Bleul, C. et al. (1996) Nature 382:829.
  3. Oberlin, E. et al. (1996) Nature 382:833.

Customers Who Viewed This Item Also Viewed...

Species: Hu
Applications: CyTOF-ready, Flow, IHC, Neut
Species: Hu
Applications: ELISA
Species: Hu, Pm, Mu, Rt
Applications: ELISA, Flow, ICC/IF, IHC, IHC-P, WB
Species: Hu
Applications: ELISA
Species: Hu(-), Mu
Applications: ELISA, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
Species: Hu
Applications: ELISA
Species: Hu, Mu, Rt
Applications: ICC, IHC, KO, Simple Western, WB
Species: Hu, Mu, Rt
Applications: CyTOF-ready, IHC, ICFlow, Simple Western, WB
Species: Hu
Applications: CyTOF-ready, Flow, ICC, Neut
Species: Ca, Hu, Mu, Po, Rb, Rt
Applications: Dual ISH-IHC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, Simple Western, WB
Species: Mu
Applications: ELISA
Species: Hu
Applications: CyTOF-ready, Flow, IHC
Species: Hu
Applications: BA
Species: Hu
Applications: CyTOF-ready, ELISA(Cap), ELISA(Det), ELISA(Sta), ICC, ICFlow, Neut, Simple Western, WB
Species: Hu
Applications: ELISA
Species: Hu
Applications: ICC, IHC, Simple Western, WB
Species: Hu
Applications: BA
Species: Hu
Applications: CyTOF-ready, Flow, IHC
Species: Mu
Applications: BA, BA

Publications for CXCL12/SDF-1 alpha (350-NS)(177)

We have publications tested in 6 confirmed species: Human, Mouse, Rat, Feline, Primate - Macaca mulatta (Rhesus Macaque), Virus.

We have publications tested in 12 applications: Binding Assay, Bioassay, Cell Culture, Control, ELISA (Standard), ELISA Control, Enzyme Assay, Functional Assay, In Vivo, Migration, Positive Control, Western Blot.

Filter By Application
Binding Assay
Cell Culture
ELISA (Standard)
ELISA Control
Enzyme Assay
Functional Assay
In Vivo
Positive Control
Western Blot
All Applications
Filter By Species
Primate - Macaca mulatta (Rhesus Macaque)
All Species
Showing Publications 1 - 10 of 177. Show All 177 Publications.
Publications using 350-NS Applications Species
Lyu, H;Shen, F;Ruan, S;Tan, C;Zhou, J;Thor, AD;Liu, B; HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel Cancer cell international 2023-09-16 [PMID: 37716943] (Bioassay, Human) Bioassay Human
Lim, HJ;Jang, WB;Rethineswaran, VK;Choi, J;Lee, EJ;Park, S;Jeong, Y;Ha, JS;Yun, J;Choi, YJ;Hong, YJ;Kwon, SM; StemRegenin-1 Attenuates Endothelial Progenitor Cell Senescence by Regulating the AhR Pathway-Mediated CYP1A1 and ROS Generation Cells 2023-08-05 [PMID: 37566085] (Bioassay, Human) Bioassay Human
Toffali, L;D'Ulivo, B;Giagulli, C;Montresor, A;Zenaro, E;Delledonne, M;Rossato, M;Iadarola, B;Sbarbati, A;Bernardi, P;Angelini, G;Rossi, B;Lopez, N;Linke, WA;Unger, A;Di Silvestre, D;Benazzi, L;De Palma, A;Motta, S;Constantin, G;Mauri, P;Laudanna, C; An isoform of the giant protein titin is a master regulator of human T lymphocyte trafficking Cell reports 2023-05-18 [PMID: 37204926] (Bioassay, Human) Bioassay Human
Shariatzadeh, M;Nagtzaam, NMA;van Vark-van der Zee, L;van Holten-Neelen, C;Verhoeven, AJM;Dehairs, J;Swinnen, JV;Leijten, F;Ten Berge, JC;Ciriano, JPM;Wong, KT;Mulder, M;Leenen, PJM;Dik, WA; Altered Functionality of Lipoprotein(a) Impacts on Angiogenesis in Diabetic Retinopathy Investigative ophthalmology & visual science 2023-05-01 [PMID: 37159194] (Bioassay, Human) Bioassay Human
YH Lai, CY Su, HW Cheng, CY Chu, LB Jeng, CS Chiang, WC Shyu, SY Chen Stem cell-nanomedicine system as a theranostic bio-gadolinium agent for targeted neutron capture cancer therapy Nature Communications, 2023-01-18;14(1):285. 2023-01-18 [PMID: 36650171] (Bioassay, Human) Bioassay Human
M Tobiume, A Mitsuhashi, A Saijo, H Ogino, T Afroj, H Ogawa, H Goto, S Sato, A Abe, K Haji, R Ozaki, H Takizawa, Y Nishioka Analysis of the chemotactic factors for tumor-infiltrating fibrocytes and their prognostic significances in lung cancer Oncology Letters, 2022-09-30;24(5):417. 2022-09-30 [PMID: 36245829] (Bioassay, Human) Bioassay Human
X Yuan, H Wu, X Li, L Chen, Y Xiao, Z Chen, G Liu, P Lu SDF?1alpha/CXCR4 signaling promotes capillary tube formation of human retinal vascular endothelial cells by activating ERK1/2 and PI3K pathways in�vitro Molecular Medicine Reports, 2022-08-10;26(4):. 2022-08-10 [PMID: 35946444] (Bioassay, Human) Bioassay Human
H Namkoong, R Edahiro, T Takano, H Nishihara, Y Shirai, K Sonehara, H Tanaka, S Azekawa, Y Mikami, H Lee, T Hasegawa, K Okudela, D Okuzaki, D Motooka, M Kanai, T Naito, K Yamamoto, QS Wang, R Saiki, R Ishihara, Y Matsubara, J Hamamoto, H Hayashi, Y Yoshimura, N Tachikawa, E Yanagita, T Hyugaji, E Shimizu, K Katayama, Y Kato, T Morita, K Takahashi, N Harada, T Naito, M Hiki, Y Matsushita, H Takagi, R Aoki, A Nakamura, S Harada, H Sasano, H Kabata, K Masaki, H Kamata, S Ikemura, S Chubachi, S Okamori, H Terai, A Morita, T Asakura, J Sasaki, H Morisaki, Y Uwamino, K Nanki, S Uchida, S Uno, T Nishimura, T Ishiguro, T Isono, S Shibata, Y Matsui, C Hosoda, K Takano, T Nishida, Y Kobayashi, Y Takaku, N Takayanagi, S Ueda, A Tada, M Miyawaki, M Yamamoto, E Yoshida, R Hayashi, T Nagasaka, S Arai, Y Kaneko, K Sasaki, E Tagaya, M Kawana, K Arimura, K Takahashi, T Anzai, S Ito, A Endo, Y Uchimura, Y Miyazaki, T Honda, T Tateishi, S Tohda, N Ichimura, K Sonobe, CT Sassa, J Nakajima, Y Nakano, Y Nakajima, R Anan, R Arai, Y Kurihara, Y Harada, K Nishio, T Ueda, M Azuma, R Saito, T Sado, Y Miyazaki, R Sato, Y Haruta, T Nagasaki, Y Yasui, Y Hasegawa, Y Mutoh, T Kimura, T Sato, R Takei, S Hagimoto, Y Noguchi, Y Yamano, H Sasano, S Ota, Y Nakamori, K Yoshiya, F Saito, T Yoshihara, D Wada, H Iwamura, S Kanayama, S Maruyama, T Yoshiyama, K Ohta, H Kokuto, H Ogata, Y Tanaka, K Arakawa, M Shimoda, T Osawa, H Tateno, I Hase, S Yoshida, S Suzuki, M Kawada, H Horinouchi, F Saito, K Mitamura, M Hagihara, J Ochi, T Uchida, R Baba, D Arai, T Ogura, H Takahashi, S Hagiwara, G Nagao, S Konishi, I Nakachi, K Murakami, M Yamada, H Sugiura, H Sano, S Matsumoto, N Kimura, Y Ono, H Baba, Y Suzuki, S Nakayama, K Masuzawa, S Namba, K Suzuki, Y Naito, YC Liu, A Takuwa, F Sugihara, JB Wing, S Sakakibara, N Hizawa, T Shiroyama, S Miyawaki, Y Kawamura, A Nakayama, H Matsuo, Y Maeda, T Nii, Y Noda, T Niitsu, Y Adachi, T Enomoto, S Amiya, R Hara, Y Yamaguchi, T Murakami, T Kuge, K Matsumoto, Y Yamamoto, M Yamamoto, M Yoneda, T Kishikawa, S Yamada, S Kawabata, N Kijima, M Takagaki, N Sasa, Y Ueno, M Suzuki, N Takemoto, H Eguchi, T Fukusumi, T Imai, M Fukushima, H Kishima, H Inohara, K Tomono, K Kato, M Takahashi, F Matsuda, H Hirata, Y Takeda, H Koh, T Manabe, Y Funatsu, F Ito, T Fukui, K Shinozuka, S Kohashi, M Miyazaki, T Shoko, M Kojima, T Adachi, M Ishikawa, K Takahashi, T Inoue, T Hirano, K Kobayashi, H Takaoka, K Watanabe, N Miyazawa, Y Kimura, R Sado, H Sugimoto, A Kamiya, N Kuwahara, A Fujiwara, T Matsunaga, Y Sato, T Okada, Y Hirai, H Kawashima, A Narita, K Niwa, Y Sekikawa, K Nishi, M Nishitsuji, M Tani, J Suzuki, H Nakatsumi, T Ogura, H Kitamura, E Hagiwara, K Murohashi, H Okabayashi, T Mochimaru, S Nukaga, R Satomi, Y Oyamada, N Mori, T Baba, Y Fukui, M Odate, S Mashimo, Y Makino, K Yagi, M Hashiguchi, J Kagyo, T Shiomi, S Fuke, H Saito, T Tsuchida, S Fujitani, M Takita, D Morikawa, T Yoshida, T Izumo, M Inomata, N Kuse, N Awano, M Tone, A Ito, Y Nakamura, K Hoshino, J Maruyama, H Ishikura, T Takata, T Odani, M Amishima, T Hattori, Y Shichinohe, T Kagaya, T Kita, K Ohta, S Sakagami, K Koshida, K Hayashi, T Shimizu, Y Kozu, H Hiranuma, Y Gon, N Izumi, K Nagata, K Ueda, R Taki, S Hanada, K Kawamura, K Ichikado, K Nishiyama, H Muranaka, K Nakamura, N Hashimoto, K Wakahara, K Sakamoto, N Omote, A Ando, N Kodama, Y Kaneyama, S Maeda, T Kuraki, T Matsumoto, K Yokote, TA Nakada, R Abe, T Oshima, T Shimada, M Harada, T Takahashi, H Ono, T Sakurai, T Shibusawa, Y Kimizuka, A Kawana, T Sano, C Watanabe, R Suematsu, H Sageshima, A Yoshifuji, K Ito, S Takahashi, K Ishioka, M Nakamura, M Masuda, A Wakabayash, H Watanabe, S Ueda, M Nishikawa, Y Chihara, M Takeuchi, K Onoi, J Shinozuka, A Sueyoshi, Y Nagasaki, M Okamoto, S Ishihara, M Shimo, Y Tokunaga, Y Kusaka, T Ohba, S Isogai, A Ogawa, T Inoue, S Fukuyama, Y Eriguchi, A Yonekawa, K Kan-O, K Matsumoto, K Kanaoka, S Ihara, K Komuta, Y Inoue, S Chiba, K Yamagata, Y Hiramatsu, H Kai, K Asano, T Oguma, Y Ito, S Hashimoto, M Yamasaki, Y Kasamatsu, Y Komase, N Hida, T Tsuburai, B Oyama, M Takada, H Kanda, Y Kitagawa, T Fukuta, T Miyake, S Yoshida, S Ogura, S Abe, Y Kono, Y Togashi, H Takoi, R Kikuchi, S Ogawa, T Ogata, S Ishihara, A Kanehiro, S Ozaki, Y Fuchimoto, S Wada, N Fujimoto, K Nishiyama, M Terashima, S Beppu, K Yoshida, O Narumoto, H Nagai, N Ooshima, M Motegi, A Umeda, K Miyagawa, H Shimada, M Endo, Y Ohira, M Watanabe, S Inoue, A Igarashi, M Sato, H Sagara, A Tanaka, S Ohta, T Kimura, Y Shibata, Y Tanino, T Nikaido, H Minemura, Y Sato, Y Yamada, T Hashino, M Shinoki, H Iwagoe, H Takahashi, K Fujii, H Kishi, M Kanai, T Imamura, T Yamashita, M Yatomi, T Maeno, S Hayashi, M Takahashi, M Kuramochi, I Kamimaki, Y Tominaga, T Ishii, M Utsugi, A Ono, T Tanaka, T Kashiwada, K Fujita, Y Saito, M Seike, H Watanabe, H Matsuse, N Kodaka, C Nakano, T Oshio, T Hirouchi, S Makino, M Egi, Biobank Ja, Y Omae, Y Nannya, T Ueno, K Katayama, M Ai, Y Fukui, A Kumanogoh, T Sato, N Hasegawa, K Tokunaga, M Ishii, R Koike, Y Kitagawa, A Kimura, S Imoto, S Miyano, S Ogawa, T Kanai, K Fukunaga, Y Okada DOCK2 is involved in the host genetics and biology of severe COVID-19 Nature, 2022-08-08;609(7928):754-760. 2022-08-08 [PMID: 35940203] (Bioassay, Human) Bioassay Human
S Leng, L Liu, W Xu, F Yang, J Du, L Ye, D Huang, L Zhang Inflammation down regulates stromal cell-derived factor 1alpha in the early phase of pulpitis Cytokine, 2022-08-02;158(0):155983. 2022-08-02 [PMID: 35930964] (Bioassay, Human) Bioassay Human
M Mastrogiov, P Vargas, T Rose, C Cuche, E Esposito, M Juzans, H Laude, A Schneider, M Bernard, S Goyard, C Renaudat, MN Ungeheuer, J Delon, A Alcover, V Di Bartolo The tumor suppressor adenomatous polyposis coli regulates T lymphocyte migration Science Advances, 2022-04-13;8(15):eabl5942. 2022-04-13 [PMID: 35417240] (Bioassay, Human) Bioassay Human
Show All 177 Publications.

Reviews for CXCL12/SDF-1 alpha (350-NS) (0)

There are no reviews for CXCL12/SDF-1 alpha (350-NS). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for CXCL12/SDF-1 alpha (350-NS) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Customers Who Bought This Also Bought

Contact Information

Product PDFs


Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.


Review this Product

Be the first to review our Recombinant Human/Rhesus Macaque/Feline CXCL12/SDF-1 alpha and receive a gift card or discount.


Gene Symbol CXCL12